BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37863847)

  • 1. A multi-institutional study to predict the benefits of DEB-TACE and molecular targeted agent sequential therapy in unresectable hepatocellular carcinoma using a radiological-clinical nomogram.
    Liu K; Zheng X; Lu D; Tan Y; Hou C; Dai J; Shi W; Jiang B; Yao Y; Lu Y; Cao Q; Chen R; Zhang W; Xie J; Chen L; Jiang M; Zhang Z; Liu L; Liu J; Li J; Lv W; Wu X
    Radiol Med; 2024 Jan; 129(1):14-28. PubMed ID: 37863847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE.
    Kong C; Zhao Z; Chen W; Lv X; Shu G; Ye M; Song J; Ying X; Weng Q; Weng W; Fang S; Chen M; Tu J; Ji J
    Eur Radiol; 2021 Oct; 31(10):7500-7511. PubMed ID: 33860832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computed tomography radiomic features and clinical factors predicting the response to first transarterial chemoembolization in intermediate-stage hepatocellular carcinoma.
    Shi ZX; Li CF; Zhao LF; Sun ZQ; Cui LM; Xin YJ; Wang DQ; Kang TR; Jiang HJ
    Hepatobiliary Pancreat Dis Int; 2024 Aug; 23(4):361-369. PubMed ID: 37429785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Radiomics Signature-Based Nomogram to Predict the Progression-Free Survival of Patients With Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Plus Radiofrequency Ablation.
    Fang S; Lai L; Zhu J; Zheng L; Xu Y; Chen W; Wu F; Wu X; Chen M; Weng Q; Ji J; Zhao Z; Tu J
    Front Mol Biosci; 2021; 8():662366. PubMed ID: 34532340
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma.
    Niu XK; He XF
    World J Gastroenterol; 2021 Jan; 27(2):189-207. PubMed ID: 33510559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a novel combined nomogram model integrating Rad-score, age and ECOG to predict the survival of patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization.
    Liu A; Liu B; Duan X; Yang B; Wang Y; Dong P; Zhou P
    J Gastrointest Oncol; 2022 Aug; 13(4):1889-1897. PubMed ID: 36092317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CT-based radiomics nomogram for prediction of survival after transarterial chemoembolization with drug-eluting beads in patients with hepatocellular carcinoma and portal vein tumor thrombus.
    Cheng S; Hu G; Jin Z; Wang Z; Xue H
    Eur Radiol; 2023 Dec; 33(12):8715-8726. PubMed ID: 37436507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma.
    Kalva SP; Pectasides M; Liu R; Rachamreddy N; Surakanti S; Yeddula K; Ganguli S; Wicky S; Blaszkowsky LS; Zhu AX
    Cardiovasc Intervent Radiol; 2014 Apr; 37(2):381-7. PubMed ID: 23754191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
    Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B
    Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
    Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
    AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
    [No Abstract]   [Full Text] [Related]  

  • 11. Prediction of initial objective response to drug-eluting beads transcatheter arterial chemoembolization for hepatocellular carcinoma using CT radiomics-based machine learning model.
    Zhang X; He Z; Zhang Y; Kong J
    Front Pharmacol; 2024; 15():1315732. PubMed ID: 38344175
    [No Abstract]   [Full Text] [Related]  

  • 12. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
    Li J; Wang N; Shi C; Liu Q; Song J; Ye X
    J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy.
    Wang M; Sun L; Han X; Ren J; Li H; Wang W; Xu W; Liang C; Duan X
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102060. PubMed ID: 36473631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Long-Term Survival Outcome in Patients With Unresectable Barcelona Clinic Liver Cancer (BCLC) Stages C and D Advanced Hepatocellular Carcinoma Treated With 40 μm Drug-Eluting Bead Transcatheter Arterial Chemoembolization.
    Wholey M; Palacios Iii R; Wholey D; Mendez A
    Cureus; 2022 Apr; 14(4):e24047. PubMed ID: 35573558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
    Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
    Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiomics nomogram for the prediction of microvascular invasion of HCC and patients' benefit from postoperative adjuvant TACE: a multi-center study.
    Zhang K; Zhang L; Li WC; Xie SS; Cui YZ; Lin LY; Shen ZW; Zhang HM; Xia S; Ye ZX; He K; Shen W
    Eur Radiol; 2023 Dec; 33(12):8936-8947. PubMed ID: 37368104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of a predictive model for short-term efficacy of transcatheter arterial chemoembolization treatment in hepatocellular carcinoma and its clinical application.
    Wei J; Wang Z
    J Cancer Res Ther; 2019; 15(4):941-946. PubMed ID: 31436256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A radiomics nomogram for predicting transcatheter arterial chemoembolization refractoriness of hepatocellular carcinoma without extrahepatic metastasis or macrovascular invasion.
    Sheen H; Kim JS; Lee JK; Choi SY; Baek SY; Kim JY
    Abdom Radiol (NY); 2021 Jun; 46(6):2839-2849. PubMed ID: 33388805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of transarterial chemoembolization with drug-eluting beads combined with systemic chemotherapy and targeted therapy in colorectal cancer liver metastasis.
    Chen YC; Huang CW; Li CC; Chang TK; Su WC; Chen PJ; Yeh YS; Chang YT; Tsai HL; Shih MP; Wang JY
    World J Surg Oncol; 2023 Dec; 21(1):378. PubMed ID: 38041083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.